Live Breaking News & Updates on Clinica Neurologica

Stay updated with breaking news from Clinica neurologica. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Wills Eye Hospital , United States , France General , United Kingdom , University Of Illinois , Thomas Jefferson University , City Of , Magali Taiel , Clinica Neurologica , Barrett Katz , Catherine Vignal Clermont , Markl Moster , Laure Blouin , Alfredoa Sadun , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Gensight Biologics , Siegfried Priglinger , Patrick Yu , Valerio Carelli , Gerard Smits , Rabih Hage , James Palmer , Gensight Biologics Euronext ,

GenSight Biologics S.A.: GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ Treatment in Phase III Trials

GenSight Biologics S.A.: GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ Treatment in Phase III Trials
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Wills Eye Hospital , United States , France General , United Kingdom , University Of Illinois , Thomas Jefferson University , City Of , Magali Taiel , Clinica Neurologica , Barrett Katz , Catherine Vignal Clermont , Markl Moster , Laure Blouin , Alfredoa Sadun , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Gensight Biologics , Siegfried Priglinger , Patrick Yu , Valerio Carelli , Gerard Smits , Rabih Hage , James Palmer , Gensight Biologics Euronext ,

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that ....

Wills Eye Hospital , United States , France General , United Kingdom , Thomas Jefferson University , City Of , Comunidad Autonoma De Cataluna , Neringa Jurkute , Magali Taiel , Clinica Neurologica , Markl Moster , Laure Blouin , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Francescom Bandello , Los Angeles , Stephanie Leruez , Gensight Biologics , Valerio Carelli , Patrick Yu , Lorena Castillo Campillo , James Palmer , Rustum Karanjia , Catherine Vignal Clermont , Jeanene Timberlake ,

GenSight Biologics Announces Publication of Results from LUMEVOQ RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology

Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology,
Ophthalmology
® gene therapy in
ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper , published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset”, is the second peer-reviewed article based on Phase III clinical trial data to document comparable bilateral improvement in visual outcomes from a unilateral injection of a gene therapy. ....

New York , United States , Wills Eye Hospital , France General , United Kingdom , Thomas Jefferson University , City Of , University Hospital , Emory University School Of Medicine , Magali Taiel , Clinica Neurologica , Piero Barboni , Barrett Katz , Catherine Vignal Clermont , Laure Blouin , Alfredoa Sadun , Marion Janic , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Jean Fran , Gensight Biologics , Patrick Yu , Valerie Biousse , Valerio Carelli ,

GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
Non-human primate study clarifies mechanism behind contralateral effect
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal
Science Translational Medicine has published results from the REVERSE pivotal Phase III clinical trial of LUMEVOQ
gene therapy in
ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate study investigating the contralateral effect of the gene therapy. The paper , published in the December issue under the title Bilateral visual improvement with unilateral gene therapy injection for ....

New York , United States , Wills Eye Hospital , France General , United Kingdom , Thomas Jefferson University , City Of , University Hospital , Magali Taiel , Yordak Salermo , Caroline Chevalier , Clinica Neurologica , Barrett Katz , Markl Moster , Laure Blouin , Alfredoa Sadun , Catherine Vignal Clermont , Marion Janic , Istituto Delle Scienze Neurologiche , Guillaume Van Renterghem , Nancyj Newman , Los Angeles , Gensight Biologics , Valerio Carelli , Harvey Masonson , Valerie Biousse ,